RE:RE:Transcript : Q4 2022 (ONCY) Conference Call March 3, 2023Andrew de Guttadauro also spoke of ONCY potentially receiving double digit royalities on aggregate CAR-T therapy + pelareorep sales. He stated that the CAR-T market in the US, EU, Japan and the ROW (ex China) is 135,000 new patients per year with a cost of US$400,000 per treatment.
Instead of paying a double digit royalty on pelareorep, conventional thinking is that Big Pharma would prefer owing the asset, and retaining the profit in-house, rather than distributing payments out through licensing agreements.